Araceli Biosciences and Ginkgo Bioworks will integrate large-scale cell imaging into the closed-loop of the Nebula laboratory
Endeavor ® will introduce the capability to generate high-speed, high-content cell data into the continuous research system of Ginkgo.
Portland, Oregon, and Boston, October 8, 2026 / PRNewswire / -- Araceli Biosciences and Ginkgo Bioworks ( NYSE : DNA ) announced today that they have integrated the Endeavor ® high-content imager from Araceli into Ginkgo's autonomous laboratory located in Boston, Nebula. Both companies stated that Endeavor is the fastest high-content imaging system in the world, and this integration will complement Nebula's existing technical capabilities by adding new cell imaging and real-time analysis functions, providing researchers with a screened and validated large-scale dataset for training and validating AI models.
Nebula is a reconfigurable automated trolley based on Ginkgo ( Reconfigurable Automation Carts, RAC ). Each RAC is a modular unit that combines a robotic arm, an automatic sample transport system, and unified control software, allowing for the addition or reconfiguration of instruments as work processes evolve. The company states that dozens of scientists use their over 100 RAC units every day for real research: after submitting an experimental plan, data can be obtained the next day. Nebula is capable of performing tasks that would normally require many scientists in an autonomous and parallel manner, operating around the clock, and occupies only about one-third of the space required by traditional lab benches to accomplish the same work.
According to the announcement, Endeavor is capable of scanning a 1536-well plate in less than 4 minutes. It has now been integrated into the RAC system of Nebula and is operating continuously in conjunction with its experiments on a regular basis. With the help of the ClaireRT ™ software from Araceli, Endeavor can perform simultaneous analysis of each well during the image collection process. If a well does not meet the preset standards, the system can alert the operator or Nebula, and it is also possible to pause the image collection in order to resolve the issue before continuing with the experiment.
Araceli Biosciences President and CEO, Matt Beaudet, stated: "The next generation of AI in the field of drug discovery requires completely different types of biological data. The laboratories themselves are undergoing changes. They are now capable of generating cell data, interpreting the information they perceive, and responding in real-time. Ginkgo is achieving this through Nebula, while Araceli brings high-resolution imaging and ultra-large-scale real-time analysis into this process."
Ginkgo Bioworks, co-founder and CEO, and Jason Kelly stated: "With each additional advanced instrument added, the value of the autonomous laboratory increases. With your own autonomous laboratory, all researchers can use Endeavor's advanced high-content imaging technology and easily connect it to all other instruments. This is precisely what an autonomous laboratory offers: the ability to integrate the best tools in the field of biology into the same system, the same software, and conduct experiments around the clock."
About Araceli Biosciences
Araceli Biosciences develops the world's fastest high-content imaging instruments, as well as artificial intelligence analysis software for automated and AI driven laboratories. The company states that its integrated solutions can provide real-time insights at the cellular level, enabling automated workflows to perform quality control and decision-making at various stages of experiments, thereby helping biotechnology and pharmaceutical companies to accelerate their R&D processes and increase confidence. For more information, please visit aracelibio.com.
About Ginkgo Bioworks
Ginkgo Bioworks is committed to developing tools that make bioengineering more accessible to everyone. The company states that its in-house laboratories use robotic systems to replace manual tasks, thereby significantly improving the productivity of researchers. Ginkgo's internal laboratories also offer their services to external parties in the form of "cloud laboratories" through their Datapoints and Solutions contract research services. For more information, please visit ginkgo.bio, or follow their social media accounts, including X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.
Ginkgo Bioworks indicates that the company develops its own laboratory infrastructure and bio-data generation services to enhance the scalability and accessibility of experimental science. Ginkgo Bioworks refers to it as a leading horizontal platform focused on cell programming, providing flexible and comprehensive services to help enterprises in various industries such as food and agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals to address challenges.
Ginkgo Bioworks Forward-looking Statement
This press release contains forward-looking statements in the meaning of the U.S. Federal Securities Laws, including statements regarding this collaboration and the capabilities of Ginkgo's independent laboratory as well as potential success. Such forward-looking statements can typically be identified by phrases such as "believes," "is able to," "expects," "potential," "anticipates," "estimates," "intends," "strategy," "future," "opportunity," "plans," "will continue," "may lead to," and similar language. Forward-looking statements are predictions, outlooks, and other statements about future events that are based on current expectations and assumptions and therefore are subject to risks and uncertainties.
The company stated that factors that could lead to significant differences between actual results and the forward-looking statements contained in this press release include, but are not limited to: whether short-term and long-term cost savings related to the integration of office and laboratory facilities can be achieved, including the ability to terminate leases or find sub-tenants for idle facilities; fluctuations in the price of Ginkgo securities due to the competitive and highly regulated nature of its industry, differences in competitor performance, and changes in laws and regulations that affect Ginkgo business; the ability to execute business plans, make forecasts, and identify and realize additional business opportunities, including those related to its solutions and tool products; the risk of a slowdown in demand for synthetic biology products; uncertainties regarding the demand for passive monitoring projects and biosafety services; changes in the biosafety industry due to technological advancements, the emergence of new competitors, and changes in industry requirements, standards, and regulations; the outcome of existing or potential litigation regarding Ginkgo; the ability to obtain expected benefits from platform projects and assets and ensure their success; the ability to successfully develop engineered cells, bioprocesses, datasets, or other deliverables; the success of customers in product development, production, or manufacturing; volatility and liquidity risks associated with holding equity in other operating companies and potential non-cash consideration received for services; potential adverse effects on business from reorganization or failure to achieve expected cost savings; uncertainties regarding government budget priorities and funding allocations by government agencies, including the potential negative impact of a U.S. government shutdown; the ability to expand on schedule and scale, increase capacity, and continue to develop autonomous laboratory (including Nebula) capabilities; the speed and scale of adoption of autonomous laboratory infrastructure in the broader life sciences and industrial biotechnology markets, and the extent to which it replaces manual laboratory work; and possible significant differences between the actual size, composition, and growth of target potential markets and the company's estimates; and the ability to integrate the autonomous laboratory platform with third-party artificial intelligence models and other technologies.As well as the speed of development and adoption of these technologies; and the ability to maintain and expand strategic partnerships and customer relationships, including those with the partners mentioned in this press release.
The company states that the aforementioned factors are not exhaustive. Investors should carefully review the “Risk Factors” section of the 10-K annual report submitted by Ginkgo to the U.S. Securities and Exchange Commission (SEC) on February 26, 2026, as well as other documents submitted from time to time by Ginkgo to SEC, which describe the aforementioned factors and other risks and uncertainties. These documents identify and discuss other significant risks and uncertainties that may lead to material differences between actual events and results and those mentioned in the forward-looking statements.
Ginkgo indicates that forward-looking statements reflect only the circumstances as of the date they are made. The company reminds readers not to rely excessively on these forward-looking statements and assumes no responsibility, nor does it intend to update or revise these statements due to new information, future events, or other reasons. Ginkgo There is no guarantee that its predictions will necessarily come true.
Araceli Biosciences Investor and Media Contact: [ email protected ]
